scispace - formally typeset
Journal ArticleDOI

Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.

Konstantinos Avgoustakis
- 30 Sep 2004 - 
- Vol. 1, Iss: 4, pp 321-333
TLDR
The ability of the PLA-Peg and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting.
Abstract
The preparation, properties and potential applications in drug delivery of biocompatible and biodegradable PLA-PEG and PLGA-PEG nanoparticles are discussed. PLA-PEG and PLGA-PEG nanoparticles have been produced by emulsification-solvent evaporation, solvent displacement and salting out methods. The nanoparticles can be stored as freeze-dried powders, but an adequate amount of a suitable lyoprotectant should be added prior lyophilisation to prevent nanoparticle aggregation and retain nanoparticle redispersibility. The nanoparticles have a core-shell structure with a PLA core and a PEG coating. Their basic colloidal properties and degradation depend on copolymer composition. The PLA-PEG and PLGA-PEG nanoparticles exhibit prolonged blood circulation following intravenous administration to animals. The composition of the nanoparticles determine their biodistribution properties, probably through its effects on the effectiveness of the PEG steric barrier and the size of the nanoparticles. The ability of the PLA-PEG and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting. The PLA-PEG and PLGA-PEG nanoparticles can be loaded with a variety of bioactive agents achieving satisfactory loading, especially in the case of hydrophobic drugs. The nanoparticles have been investigated for the treatment of infectious diseases and cancer, the intravenous and mucosal delivery of proteins, and oligonucleotide and gene delivery. The results have been encouraging and PLA-PEG and PLGA-PEG nanoparticle formulations, improving the therapeutic potential of both established and new drugs, may be expected to be available in the near future.

read more

Citations
More filters
Journal ArticleDOI

Single-step process to produce surface-functionalized polymeric nanoparticles.

TL;DR: This novel process to produce functionalized polymeric NPs derived from nonfunctional polymers in a single step is described and is expected to enable complex surface engineering of NP chemistry that hitherto was impossible using existing approaches.
Journal ArticleDOI

Development of polymeric irinotecan nanoparticles using a novel lactone preservation strategy.

TL;DR: Owing to the presence of hydrophilic PEG outer layer and drug-loaded hydrophobic PLGA core, NPs conferred excellent plasma stability and prolonged the retention time of IRT by more than 10-fold as compared to free IRT.
Journal ArticleDOI

Enhanced thrombolysis using tissue plasminogen activator (tPA)-loaded PEGylated PLGA nanoparticles for ischemic stroke

TL;DR: The tPA-PEG-PLGA NPs could be a robust nanomedicine for enhanced thrombolytic therapy of ischemic stroke because of its biodegradable and biocompatible polymeric nanoparticles.
Journal ArticleDOI

A tissue factor targeted nanomedical system for thrombi-specific drug delivery.

TL;DR: The pharmacokinetic study demonstrated that EGF1-EGFP-NP has the same blood circulation time as NP and in vitro cell viability experiment and in vivo coagulation ability confirmed that the EGF 1-EG FP-NP was safe.
Journal ArticleDOI

Pegylation effect of chitosan based polyplex on DNA transfection.

TL;DR: The aim of this study was to develop hepatocyte-targeting non-viral polymeric nono-carriers for gene delivery by grafted chitosan as the main polymer on an asialoglycoprotein receptor recognized sugar.
Related Papers (5)